NCT03483961 - Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults | Biotech Hunter

Enrollment

445

Participants

Timeline

Start Date

April 18, 2018

Primary Completion Date

September 14, 2020

Study Completion Date

September 21, 2020

Conditions

Chikungunya Virus Infection

Interventions

BIOLOGICAL

CHIKV VLP/unadjuvanted

Vaccine consists of virus-like particles of chikungunya virus antigens

BIOLOGICAL

CHIKV VLP/adjuvanted

Adjuvanted formulation includes Alhydrogel

BIOLOGICAL

Placebo

Placebo is vaccine diluent alone

Trial Locations (3)

The Center for Pharmaceutical Research, Kansas City

Johnson County Clin-Trials, Lenexa

Advanced Clinical Research, West Jordan